SWOG S0910: A Phase 2 Trial of Clofarabine/Cytarabine/Epratuzumab for Relapsed/Refractory Acute Lymphocytic Leukaemia

Precursor B-acute lymphoblastic leukaemias (pre-B ALLs) comprise the majority of ALLs and virtually all blasts express CD22 in the cytoplasm and on the cell surface. In the present study (Southwestern Oncology Group S0910), we evaluated the addition of epratuzumab, a humanized monoclonal antibody ag...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Advani, Anjali S., McDonough, Shannon, Coutre, Steven, Wood, Brent, Radich, Jerald, Mims, Martha, O’Donnell, Margaret, Elkins, Stephanie, Becker, Michael, Othus, Megan, Appelbaum, Frederick R.
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4209396/
https://ncbi.nlm.nih.gov/pubmed/24579885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.12778
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares